| |
| October 1, 2008 |
| |
| If
you are unable to view these articles or access the links,
please visit the ASBMT Web Site at www.asbmt.org to read this
issue. To be removed from this distribution list, please see
instructions at bottom. |
| |
 |
Top
Stories |
| |
|
 |
Legislation and Regulation |
| |
|
 |
Clinical
Research |
| |
|
 |
Biopharmaceutical News |
| |
|
 |
Association
News |
| |
|
 |
Calendar |
| |
|
 |
Job &
Fellowship Connections |
| |
|
 |
Monthly Journal |
| |
|
 |
eNews
Archives |
|
|
| |
 |
| |
 |
|
|
| |
BMT
Tandem Meetings
Feb. 11-15, 2009
Tampa, Florida |
| |
|
|
|
Calendar |
|
• October
International Society of Paediatric Oncology (ISPO)
40th Annual Meeting
Oct. 2-6
Estrel Convention Center
Berlin, Germany
Molecular Prognostic Markers in Acute Myeloid Leukemia
European School of Haematology
Oct. 3-5
Pullman Mandelieu Royal Casino Hotel
Mandelieu, France
American Association of Blood Banks (AABB)
2008 Annual Meeting
Oct. 4-7
Palais des Congrès de Montréal
Montreal, Canada
Aging and Cancer
American Association for Cancer Research (AACR)
Oct. 6-7
Union League Club
New York, New York
9th International Congress on Cell Biology
Korean Society for Molecular and Cellular Biology
Oct. 7-9
COEX Convention & Exhibition Center
Seoul, Korea
Targeted and Tailored Therapies in Hematology/Oncology
Loyola University Chicago Stritch School of Medicine
Oct. 11
McDonald’s Hamburger University
Oak Brook, Illinois
Cytokines 2008: Cytokines in Cancer & Infectious Diseases
International Cytokine Society (ICS)
Oct. 12-16
Fairmont Queen Elizabeth Hotel
Montreal, Canada
International Congress on Hematologic Malignancies: Lymphoma and Myeloma
Imedex
Oct. 16-18
Waldorf-Astoria Hotel
New York, New York
Biology and Clinical Applications of Cord Blood Cells
European School of Haematology, Eurocord, International NetCord Foundation, European Group for Blood and Marrow Transplantation, University of Texas M.D. Anderson
Cancer Center, and Duke University
Oct. 16-19
Pullman Mandelieu Royal Casino Hotel
Mandelieu, France
International Society of Hematology (ISH)
32nd World Congress
Oct. 19-23
Bangkok Convention Centre at CentralWorld
Bangkok, Thailand
Symposium on Molecular Targets and Cancer Therapeutics
American Association for Cancer Research (AACR),
National Cancer Institute (NCI),
and European Organisation for Research and Treatment of Cancer (EORTC)
Oct. 21-24
Geneva Palexpo
Geneva, Switzerland
The Future of Cancer Research: Science and Patient Impact
American Association for Cancer Research (AACR)
Oct. 27-28
Roswell Park Cancer Institute
Buffalo, New York
American Society for Histocompatibility and Immunogenetics (ASHI)
34th Annual Meeting
Oct. 27-31
Sheraton Toronto
Toronto, Canada
61st Annual Symposium on Cancer Research
M.D. Anderson Cancer Center
Oct. 30-Nov. 1
R. Lee Clark Clinic
Houston, Texas
• November
Translational Cancer Medicine 2008: Bridging the Lab and Clinic in Cancer Medicine
American Association for Cancer Research
Nov. 3-6
ICC Jerusalem International Convention Center
Jerusalem, Israel
Innovative Cancer Therapy for Tomorrow
Chemotherapy Foundation
Nov. 4-8
Marriott Marquis Hotel
New York, New York
National Marrow Donor Program (NMDP)
20th Annual Council Meeting
Nov. 7-9
Hilton Minneapolis Hotel
Minneapolis, Minnesota
4th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes
Imedex, LLC
Nov. 8-10
Marriott New York – Brooklyn Bridge
New York, New York
American Society for Human Genetics (ASHG)
58th Annual Meeting
Nov. 11-15
Pennsylvania Convention Center
Philadelphia, Pennsylvania
European Society of Gene Therapy (ESGT)
16th Annual Congress
Nov. 13-16
Concertgebouw Brugge
Bruges, Belgium
• December
Tumor Immunology: New Perspectives
American Association for Cancer Research (AACRS)
Dec. 2-5
Hyatt Regency Miami
Miami, Florida
American Society of Hematology (ASH)
50th Annual Meeting
Dec. 6-9
Moscone Convention Center
San Francisco, California
American Society for Cell Biology (ASCB)
48th Annual Meeting
Dec. 13-17
Moscone Center
San Francisco, California
2009 • January
Mobilizing Cellular Immunity for Cancer Therapy
Keystone Symposia
Jan. 11-16
Snowbird Resort
Snowbird, Utah
Emerging Tumor Supressors
Keystone Symposia
Jan. 25-29
Sagebrush Inn and Conference Center
Taos, New Mexico
Phacilitate Cell & Gene Therapy Forum 2009
Jan. 26-28
The Grand Hyatt
Washington, D.C.
• February
BMT Tandem Meetings
(Combined ASBMT and CIBMTR annual meetings)
Feb. 11-15
Tampa Convention Center
Tampa, Florida
• March
Emergence to Convergence: Management of High Risk Donors and Recipients
American Society of Transplantation (AST)
22nd Annual Winter Symposium
March 4-5
Fairmont Banff Springs
Banff, Alberta, Canada
Regenerative Medicine: Advancing Next Generation Therapies
13th Annual Hilton Head Workshop
March 5-6
Sea Pines Resort
Hilton Head Island, South Carolina
Canadian Society of Transplantation (CST)
Annual Scientific Meeting
March 5-8
Fairmont Banff Springs
Banff, Alberta, Canada
Association of Community Cancer Centers
35th Annual Meeting
March 18-21
Gaylord National Resort and Convention Center
Washington, D.C.
Acute Leukemia Forum 2009
Hemedicus
March 20
Parc 55 Hotel
San Francisco, California
Targeted Cancer Therapies
Keystone Symposia
March 27-April 1
Whistler Conference Centre
Whistler, British Columbia, Canada
|
|
|
|
|
|
|
| |
Top
Stories |
| |
Pentagon funding $250 million of adult stem cell research
The Pentagon is investing $250 million in a five-year initiative to research how adult stem cells stop scarring, rebuild tendons and grow bones. The research is intended to aid injured military personnel. 
Patent issued in Japan for method to create stem cells
Kyoto University has obtained a patent in Japan on the fundamental techniques of a method for creating induced pluripotent stem cells that involves injecting a genetic cocktail into skin cells. The technique was created using cells from mice, and later tested on human cells. 
Survival rates increase for children with three blood cancers
Survival rates for children with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia and non-Hodgkin lymphoma have improved in the United States since the 1990s. According to researchers in Germany, five-year survival rates for patients with these conditions were 88 percent, 60 percent and 88 percent respectively. 
|
| |
A Word from President Helen Heslop, MD
I have lived in Houston for 10 years, but until this past month I had experienced only one hurricane in my life. Would you believe that was more than 20 years ago, in London?
That was an unnamed Category 1 storm that the BBC weatherman famously failed to predict. I slept through it. There was severe damage to trees, but no major power outages because power lines in England are underground.
Here in Houston we monitor and track named storms when they reach the Gulf days ahead of landfall. In 2001, tropical storm Allison caused major flooding, and three years ago Category 5 Rita was forecast to hit Galveston. We activated our emergency plans, with the fresh memory of Katrina-devastated New Orleans, and more than 2 million people evacuated the city. But at the last minute, Rita weakened to Category 3 and turned east. We escaped with only tropical storm-force winds. A great relief, to be sure, although I felt guilty when one of my patients from Beaumont showed me photos of his flattened house.
This year we had more narrow misses: All of the Texas Medical Center institutions closed for Eduardo in August, but that storm took the same path as Rita and landed to the east. Gustav ended up hitting Louisiana. Hanna went to the East Coast.
But then came Ike.
The predicted landfall oscillated between Florida and the Mexican border, but by Wednesday, Sept. 10, Ike veered back toward Galveston. The next morning the state ordered evacuations from Galveston and South Houston, and the National Hurricane Center and President Bush both warned of near-certain death for those who failed to comply. I was supposed to travel to Stanford, but canceled the trip to implement our hurricane disaster plan.
Houston hospitals have comprehensive plans, and our BMT program superimposes our own FACT-required plan upon these. Although we have implemented it frequently over the past few years, the details differ each time. Immediately before Rita we had four NMDP donor collections scheduled and our NMDP coordinator, Marsha, in a tour-de-force performance with the NMDP, rescheduled them all to get the products out before the airport closed.
This time we had no NMDP donors scheduled, but we had to decide whether to postpone transplant admissions and plan how to complete our Friday infusions before the hospitals closed down at midday. We made sure there was additional liquid nitrogen for the GMP facility, rescheduled outpatient clinics and updated our emergency contact lists.
There is a specific hurricane vocabulary with terms such as “rideout teams,” “relief teams” and “recovery teams.” We assigned these and then, in Texas vocabulary, “hunkered down” for the winds to begin. I was on the recovery team, so I stayed with local friends.
We lost power early on Friday night when the winds were only tropical-storm force and before we had finished cooking dinner. To avoid spoilage by loss of refrigeration, we ate smoked salmon and partially roasted potatoes, washing the lumps down with a couple bottles of Bollinger. We spent 10 hours in an internal room with no windows, following the storm’s progress on wind-up radios. Ike, by then a Category 2 hurricane, was extremely loud and exponentially stronger than my long-ago London Category 1.
The next morning, when the winds had decreased, we navigated flooded streets, fallen and precarious trees, downed power lines and non-functional traffic signals to get to the hospitals. More than 2 million households had lost power, but the Texas Medical Center has an underground supply and never had to switch to generators. The water pressure was low for 24 hours but, in general, the hospitals all did very well.
A major challenge was communications. Telephone landlines were working, but few people still rely on line-powered phones. Most cell phone towers were without power, so the most reliable communication was via Blackberry. (Our always-prescient nurse practitioners had successfully lobbied for Blackberries a few months ago and were able to use them to keep in contact with patients.)
Now, two weeks later, about 60 percent of staff and patients have power at home, but schools are still closed, so many staff have childcare issues and many have damaged homes to repair.
On a trip to the NIH, I exchanged hurricane stories with some M.D. Anderson faculty. My three days without electricity paled compared with Steve Kornblau’s account of his flooded house and finding his boat in the backyard, and Laurence Cooper’s description of having to get out his chain saw to clear fallen trees from his street and fuelling his generator every eight hours.
Every disaster offers lessons for next time. Among my lessons from Ike are:
1. Transplant unit-specific disaster plans are not just a FACT requirement, but actually help when emergency strikes.
2. Other subspecialties should also develop unit-specific disaster plans.
3. Hurricane recovery is not an event but a process. Expect continued staff shortages caused by evacuation, childcare and housing issues long after the official emergency ends.
4. It is good to have a fridge in your office at work.
5. Keep an old fashioned phone to substitute for your cordless one when there is no power.
6. There are good reasons to join the Blackberry Brigade. I may have to sign up for a users group.
7. The transplant community is very good about offering help. Thanks to all of you who contacted us.
– Helen
|
|
| |
Legislation and Regulation |
| |
Bill would fund research, treatment of bone marrow failure
Rep. Doris O. Matsui (D-Calif.) has introduced the Bone Marrow Failure Disease Research and Treatment Act (HR 6884) that would bring together resources of several federal agencies to advance understanding and treatments for aplastic anemia, myelodysplastic syndromes and acute myeloid leukemia. |
| |
Clinical Research |
| |
Stem cells reduce brain damage from interrupted blood supply
Human stem cells derived from bone marrow can reduce the brain damage caused by the interruption in blood supply that occurs during a heart attack or stroke. According to a report in the Sept. 23 issue of the Proceedings of the National Academy of Sciences, human mesenchymal stromal cells switch on and off different genes, suppressing harmful inflammation and immune system reactions. 
Blocking receptor restores vigor to immune cells
Scientists have discovered a way to restore vigor to killer T cells by blocking a receptor known as programmed death-1. According to a report in the online edition of the Proceedings of the National Academy of Sciences, using an antibody to block the receptor dramatically restored immunity in mice suffering from chronic infections. 
Molecules cause differentiation of stem cells
Two synthetic molecules have been found to coax stem cells to differentiate. The molecules, called EC19 and EC23, are effective at producing neurons and epithelial cells, respectively. According to a report in the Sept. 18 issue of Organic and Biomolecular Chemistry, these molecules are not sensitive to light and therefore do not degrade. 
Common cold virus can carry genes to transform cells
Using a common cold virus to carry genes into ordinary mouse cells, researchers have made the cells look and act like embryonic stem cells. According to a report in the advance online edition of Science, using an adenovirus on mouse skin and liver cells induced the cells to look and act like induced pluripotent stem cells, which in turn look and act like embryonic stem cells. 
|
| |
Biopharmaceutical News |
| |
Biovitrum acquires two products, exclusive license from Amgen
Biovitrum AB and Amgen have entered into an agreement under which Biovitrum will acquire biological therapeutic products Kepivance (palifermin) and Stemgen (ancestim) from Amgen. Biovitrum also will obtain a worldwide exclusive license to Kineret (anakinra) for its current approved indication. 
Adult stem cell compound moving toward human clinical trials
ImmuneRegen BioSciences Inc. recently received $5 million of institutional financing, which the company intends to use to move its Homspera adult stem cell compound into human clinical trials. Studies in animals indicate the compound can regenerate and strengthen the immune system and enhance wound healing. |
| |
Association
News |
| |
Forum considers methods for treatment outcome reporting
Nearly 60 representatives of the BMT community responded to an invitation from CIBMTR and ASBMT to participate in a Center-Specific Outcome Analysis Planning Forum last week in Milwaukee.
Managing EBV and adenovirus infections post transplant
This month’s program in the series of ASBMT Online Seminars is “Monitoring and Managing EBV and Adenovirus Infections Post Transplant” produced by Baylor College of Medicine, Methodist Hospital and Texas Children’s Hospital. Download the program to a video iPod or standard desktop or laptop computer. Upon completion of the program and its evaluation, print out a certificate for an hour of Category 1 CME credit. 
Early registration deadline is Oct. 8 for BMT Tandem Meetings
Oct. 8 is the deadline for early registration for the 2009 BMT Tandem Meetings, to be held Feb. 11-15 in Tampa. After that date, standard registration rates apply. On a single Web page, navigate to meeting registration, housing reservations, preliminary program, abstract submission and parallel conferences. 
Abstract submission deadline is Oct. 8 for Tampa meeting
Abstracts for the 2009 BMT Tandem Meetings are being accepted through Oct. 8. Sixty-six authors whose abstracts receive the highest scores from the review committees will be invited to give oral presentations. Other accepted abstracts will receive poster invitations. ASBMT will provide travel grants of $1,000 each to young investigators whose abstracts are accepted for oral presentation.
NMDP celebrates 20 years with BBMT supplement
A supplement to the September issue of Biology of Blood and Marrow Transplantation celebrates the 20th anniversary of the National Marrow Donor Program. Written by leaders in the field of blood and marrow transplantation, the articles describe the many accomplishments of the NMDP and expected future directions for unrelated-donor marrow, peripheral blood stem cell and cord blood transplantation. 
Research grant announced for young investigators
A $60,000 research grant is available to young investigators, sponsored by ASBMT and Otsuka America Pharmaceuticals, Inc. The deadline is Dec. 1.
Oct. 24 deadline for next Amy Strelzer Manasevit award
The Marrow Foundation and the National Marrow Donor Program (NMDP) are accepting applications for the next Amy Strelzer Manasevit Research Program for the Study of Post-Transplant Complications. This year one award will be presented for a maximum of $240,000 over a three-year period. The program for scientists and clinicians early in their careers is intended to advance the understanding of events occurring after allogeneic hematopoietic cell transplantation. Proposals must be submitted by Oct 24.
Free ASBMT membership for trainees
Postdoctoral fellows and physicians-in-training for blood and marrow transplantation are eligible for free membership in the American Society for Blood and Marrow Transplantation. During October and November, annual dues are waived for new trainees who apply for membership in the Society. The program is made possible this year through a grant from Otsuka America Pharmaceuticals, Inc.
Cell-based therapies for osteonecrosis of the femoral head
Osteonecrosis of the femoral head is a disabling condition and a known complication of hematopoietic cell transplants. A review in the October issue of Biology of Blood and Marrow Transplantation provides an update on osteonecrosis and tells how cell therapy, especially with mesenchymal stromal cells, is a promising new treatment.
|
| |
|